Free tool
FAERS Monitor: Zortress
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021560 or its brand name (Zortress, Everolimus). Reports on generic versions are filed under their own applications.
Reports
18,496
Serious
16,082
87% of reports
Hospitalization
7,003
Death reported
2,839
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- malignant neoplasm progression1,602
- off label use1,422
- diarrhoea1,307
- drug ineffective1,035
- death916
- fatigue898
- nausea816
- product use in unapproved indication764
- disease progression762
- dyspnoea704
- pyrexia682
- pneumonia667
- vomiting656
- anaemia573
- drug interaction564
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2006 | 5 |
| 2007 | 15 |
| 2008 | 33 |
| 2009 | 88 |
| 2010 | 120 |
| 2011 | 362 |
| 2012 | 457 |
| 2013 | 428 |
| 2014 | 501 |
| 2015 | 744 |
| 2016 | 722 |
| 2017 | 825 |
| 2018 | 1,244 |
| 2019 | 1,401 |
| 2020 | 1,934 |
| 2021 | 1,624 |
| 2022 | 1,780 |
| 2023 | 1,834 |
| 2024 | 1,800 |
| 2025 | 1,391 |
| 2026 | 1,186 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,035,663 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| malignant neoplasm progressionSignal | 1,602 | 18.1 | 17.2 | 25,513 |
| disease progressionSignal | 762 | 7.4 | 6.9 | 4,181 |
| drug interactionSignal | 564 | 4.1 | 3.7 | 1,300 |
| product use in unapproved indicationSignal | 764 | 3.5 | 3.3 | 1,383 |
| anaemiaSignal | 573 | 3.4 | 3.2 | 987 |
| pneumoniaSignal | 667 | 2.3 | 2.2 | 520 |
| diarrhoeaSignal | 1,307 | 2.3 | 2.2 | 993 |
| pyrexiaSignal | 682 | 2.2 | 2.1 | 476 |
| off label use | 1,422 | 1.8 | 1.8 | 576 |
| vomiting | 656 | 1.6 | 1.5 | 145 |
| dyspnoea | 704 | 1.4 | 1.3 | 87 |
| fatigue | 898 | 1.3 | 1.2 | 69 |
| death | 916 | 1.2 | 1.1 | 34 |
| nausea | 816 | 1.2 | 1.1 | 21 |
| drug ineffective | 1,035 | 0.9 | 0.8 | 14 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.